Tessa Therapeutics, a Temasek-backed clinical stage biotech company, is set to enter liquidation after failing to raise more funding for the development of its cancer treatment cell therapies or find a strategic buyer amid a market downturn, The Business Times reported citing the company’s letter to shareholders.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
